We’ll hope to cover all the goofily-twisted pretzel logic by which CEO Hassan and his top officers make their case that the proposed reverse merger with Merck is actually [yet another] triumph — engineered by this vastly-experienced, and entirely selfless pharmaceuticals management team. Technically, the merger is not on the agenda — but it will undoubtedly come up — as will questions about the recently-mailed Executive Compensation Survey, so do tune in.
. . . .CEO Fred Hassan. . . at least $51,399,546. . . in change of control payments. . . [times 1.9, or $97.6 million, in total package value -- minimum]. . . .
Wow — the shareholders should really ask about that.
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.